Cargando…
Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants
Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4 + T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants on...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919596/ https://www.ncbi.nlm.nih.gov/pubmed/27428434 http://dx.doi.org/10.1016/j.ebiom.2016.04.040 |
_version_ | 1782439273647046656 |
---|---|
author | Lin, Nina Gonzalez, Oscar A. Registre, Ludy Becerril, Carlos Etemad, Behzad Lu, Hong Wu, Xueling Lockman, Shahin Essex, Myron Moyo, Sikhulile Kuritzkes, Daniel R. Sagar, Manish |
author_facet | Lin, Nina Gonzalez, Oscar A. Registre, Ludy Becerril, Carlos Etemad, Behzad Lu, Hong Wu, Xueling Lockman, Shahin Essex, Myron Moyo, Sikhulile Kuritzkes, Daniel R. Sagar, Manish |
author_sort | Lin, Nina |
collection | PubMed |
description | Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4 + T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants only emerge after profound immunological damage. We show that exclusively CXCR4- as compared to cocirculating CCR5-utilizing variants are less sensitive to neutralization by both contemporaneous autologous plasma and plasma pools from individuals that harbor only CCR5-using HIV-1. The CXCR4-utilizing variants, however, do not have a global antigenic change because they remain equivalently susceptible to antibodies that do not target coreceptor binding domains. Studies with envelope V3 loop directed antibodies and chimeric envelopes suggest that the neutralization susceptibility differences are potentially influenced by the V3 loop. In vitro passage of a neutralization sensitive CCR5-using virus in the presence of autologous plasma and activated CD4 + T cells led to the emergence of a CXCR4-utilizing virus in 1 of 3 cases. These results suggest that in some but not necessarily all HIV-1 infected individuals humoral immune pressure against the autologous virus selects for CXCR4-using variants, which potentially accelerates disease progression. Our observations have implications for using antibodies for HIV-1 immune therapy. |
format | Online Article Text |
id | pubmed-4919596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-49195962016-06-30 Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants Lin, Nina Gonzalez, Oscar A. Registre, Ludy Becerril, Carlos Etemad, Behzad Lu, Hong Wu, Xueling Lockman, Shahin Essex, Myron Moyo, Sikhulile Kuritzkes, Daniel R. Sagar, Manish EBioMedicine Research Paper Although both C-C chemokine receptor 5 (CCR5)- and CXC chemokine receptor 4 (CXCR4)-using HIV-1 strains cause AIDS, the emergence of CXCR4-utilizing variants is associated with an accelerated decline in CD4 + T cells. It remains uncertain if CXCR4-using viruses hasten disease or if these variants only emerge after profound immunological damage. We show that exclusively CXCR4- as compared to cocirculating CCR5-utilizing variants are less sensitive to neutralization by both contemporaneous autologous plasma and plasma pools from individuals that harbor only CCR5-using HIV-1. The CXCR4-utilizing variants, however, do not have a global antigenic change because they remain equivalently susceptible to antibodies that do not target coreceptor binding domains. Studies with envelope V3 loop directed antibodies and chimeric envelopes suggest that the neutralization susceptibility differences are potentially influenced by the V3 loop. In vitro passage of a neutralization sensitive CCR5-using virus in the presence of autologous plasma and activated CD4 + T cells led to the emergence of a CXCR4-utilizing virus in 1 of 3 cases. These results suggest that in some but not necessarily all HIV-1 infected individuals humoral immune pressure against the autologous virus selects for CXCR4-using variants, which potentially accelerates disease progression. Our observations have implications for using antibodies for HIV-1 immune therapy. Elsevier 2016-05-05 /pmc/articles/PMC4919596/ /pubmed/27428434 http://dx.doi.org/10.1016/j.ebiom.2016.04.040 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Lin, Nina Gonzalez, Oscar A. Registre, Ludy Becerril, Carlos Etemad, Behzad Lu, Hong Wu, Xueling Lockman, Shahin Essex, Myron Moyo, Sikhulile Kuritzkes, Daniel R. Sagar, Manish Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants |
title | Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants |
title_full | Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants |
title_fullStr | Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants |
title_full_unstemmed | Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants |
title_short | Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants |
title_sort | humoral immune pressure selects for hiv-1 cxc-chemokine receptor 4-using variants |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919596/ https://www.ncbi.nlm.nih.gov/pubmed/27428434 http://dx.doi.org/10.1016/j.ebiom.2016.04.040 |
work_keys_str_mv | AT linnina humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT gonzalezoscara humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT registreludy humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT becerrilcarlos humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT etemadbehzad humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT luhong humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT wuxueling humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT lockmanshahin humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT essexmyron humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT moyosikhulile humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT kuritzkesdanielr humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants AT sagarmanish humoralimmunepressureselectsforhiv1cxcchemokinereceptor4usingvariants |